Pfizer chief corporate affairs officer Sally Susman is departing the company after roughly two decades, CEO Albert Bourla ...

Changing market conditions and consumer tastes and preferences have weighed on these businesses. Investors can learn a lot ...

Some two dozen biotech developers of PROTACs, molecular glues and other types of protein-degrading drugs have sprung up over ...

A former Pfizer scientist was subpoenaed Monday by House Republicans over allegations that there was a conspiracy among ...

Pfizer recently announced positive results from the BASIS study, the global phase 3 trial evaluating Hympavzi in young adults ...

The House Judiciary Committee subpoenaed a former Pfizer executive who allegedly claimed senior members of the company ...

At recent prices, the yield you receive from Pfizer is more than four times the amount you'd receive from the average ...

The House Judiciary Committee has subpoenaed a former Pfizer executive who is considered central to its investigation into an ...

BRUSSELS (CNS) — European Commission President Ursula von der Leyen defended herself before the European Parliament Monday as ...

Pfizer PFE has committed significant resources for the development of treatments in the fields of oncology, internal medicine ...

Discover why options trading trends, robust R&D, and strong free cash flow position Pfizer Inc. for growth. Click for my ...

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment ...